Meeting
2013 Genitourinary Cancers Symposium
Trends in use of intravenous bisphosphonates in patients with prostate cancer and newly diagnosed metastases to bone in two large U.S. integrated health systems.
Authors
Lois Lamerato
Henry Ford Health System, Detroit, MI
Lois Lamerato , Andrew Glass , Kathryn E. Richert-Boe , John Edelsberg , Greg G. Wolff , Natalie Czapski , Tracy Dodge , Andrea Lopez , Karen Chung , Akshara Richhariya , Gerry Oster
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session B: Prostate, Penile, Urethral, and Testicular Cancer, and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, and Testicular Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 31, 2013 (suppl 6; abstr 192)
DOI
10.1200/jco.2013.31.6_suppl.192
Abstract #
192
Poster Bd #
B16
Abstract Disclosures
Similar Posters
Poster
2021 Genitourinary Cancers Symposium
Use of bone modifying agents in patients with metastatic castrate-sensitive prostate cancer.
First Author: Aaron Philip Mitchell
Poster
2017 Genitourinary Cancers Symposium
Evaluation of treatment patterns and costs for patients with prostate cancer and bone metastases.
First Author: Adriana Valdarrama
Poster
2015 Genitourinary Cancers Symposium
Bone metabolism biomarkers in men with advanced prostate cancer (PC) and bone metastases treated with denosumab versus zoledronic acid (ZA).
First Author: Matthew Raymond Smith
Poster
2014 Palliative and Supportive Care in Oncology Symposium
A randomized, double-blind trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronate in patients with high-risk bone metastases from breast cancer (The Odyssey Study).
First Author: Carmel Maree Jacobs